The estimated Net Worth of Charles A. Deignan is at least $1.28 Million dollars as of 18 January 2024. Mr. Deignan owns over 12,900 units of Clearside Biomedical Inc stock worth over $503,907 and over the last 8 years he sold CLSD stock worth over $115,018. In addition, he makes $661,207 as Chief Financial Officer at Clearside Biomedical Inc.
Sign up
Mr. Deignan CLSD stock SEC Form 4 insiders trading
Charles has made over 14 trades of the Clearside Biomedical Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 12,900 units of CLSD stock worth $16,512 on 18 January 2024.
The largest trade he's ever made was exercising 34,090 units of Clearside Biomedical Inc stock on 13 September 2023 worth over $13,636. On average, Charles trades about 5,329 units every 111 days since 2016. As of 18 January 2024 he still owns at least 384,662 units of Clearside Biomedical Inc stock.
You can see the complete history of Mr. Deignan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Deignan biography
Charles A. Deignan serves as Chief Financial Officer of the Company. From 2009 to 2011, Mr. Deignan was Vice President of Finance and Administration for Salutria Pharmaceuticals. Previously, from 1999 to 2009, Mr. Deignan served in a number of roles with AtheroGenics, Inc., a publicly held biopharmaceutical company, including as its Vice President of Finance and Administration. Prior to that, he held management positions at AAIPharma, Inc. and Schering-Plough. Mr. Deignan received his B.S. degree in Business Administration from Boston University.
What is the salary of Charles Deignan?
As the Chief Financial Officer of Clearside Biomedical Inc, the total compensation of Charles Deignan at Clearside Biomedical Inc is $661,207. There are 3 executives at Clearside Biomedical Inc getting paid more, with George Lasezkay having the highest compensation of $1,059,190.
How old is Charles Deignan?
Charles Deignan is 55, he's been the Chief Financial Officer of Clearside Biomedical Inc since 2012. There are 9 older and 4 younger executives at Clearside Biomedical Inc. The oldest executive at Clearside Biomedical Inc is Nancy Hutson, 70, who is the Independent Director.
What's Charles Deignan's mailing address?
Charles's mailing address filed with the SEC is C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA, GA, 30005.
Insiders trading at Clearside Biomedical Inc
Over the last 8 years, insiders at Clearside Biomedical Inc have traded over $11,999,807 worth of Clearside Biomedical Inc stock and bought 4,477,928 units worth $22,264,136 . The most active insiders traders include Bradford T Whitmore, Clay Thorp, and Venture Advisors Iv Sbic, L.... On average, Clearside Biomedical Inc executives and independent directors trade stock every 30 days with the average trade being worth of $82,593. The most recent stock trade was executed by Ngai Hang Victor Chong on 24 June 2024, trading 23,500 units of CLSD stock currently worth $24,910.
What does Clearside Biomedical Inc do?
clearside biomedical, inc. is a pharmaceuticals company located in 1220 old alpharetta rd., suite 300, alpharetta, ga, united states.
What does Clearside Biomedical Inc's logo look like?
Complete history of Mr. Deignan stock trades at Clearside Biomedical Inc
Clearside Biomedical Inc executives and stock owners
Clearside Biomedical Inc executives and other stock owners filed with the SEC include:
-
George Lasezkay,
President, Chief Executive Officer, Director -
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.,
Pres, CEO & Director -
Dr. George M. Lasezkay Pharm.D., Pharma.D., J.D.,
Pres, CEO & Director -
Charles Deignan,
Chief Financial Officer -
Dr. Thomas A. Ciulla M.B.A., M.D.,
Chief Medical Officer & Chief Devel. Officer -
Charles A. Deignan,
Chief Financial Officer -
Jenny Kobin,
IR Contact Officer -
Clay Thorp,
Independent Director -
Nancy Hutson,
Independent Director -
William Humphries,
Independent Director -
Jeffrey Edwards,
Independent Director -
Richard Croarkin,
Independent Director -
Christy Shaffer,
Independent Chairman of the Board -
Susan L. Coultas Ph.D.,
Chief Clinical Officer -
Rick McElheny,
VP of Corp. Devel. -
Leslie B. Zacks,
Gen. Counsel, Chief Compliance Officer & Sec. -
Jenny R. Kobin,
Head of Investor Relations -
Venture Advisors Iii, Llc H...,
-
Venture Advisors Iv Sbic, L...,
-
Venture Advisors Iii, Llc H...,
-
Evgeny Zaytsev,
Director -
Daniel H. White,
President and CEO -
Investments S.A.R.L.Rusnano...,
-
Derek Yoon,
Director -
Gerald D. Cagle,
Director -
Venture Advisors Iv Sbic, L...,
-
Glenn Noronha,
Executive Vice President, R&D -
Thomas Ciulla,
Chief Medical Officer -
Brion S. Raymond,
Chief Commercial Officer -
Anthony S Gibney,
-
Bradford T Whitmore,
10% owner -
Ngai Hang Victor Chong,
Chief Medical Officer -
Benjamin R Yerxa,